Loading organizations...
§ Private Profile · 4902 Headquarters Point, Suite 300. San Diego, CA 92121
Precision medicines for immune-mediated inflammatory and fibrotic diseases.
Mirador Therapeutics develops precision medicines specifically for immune-mediated inflammatory and fibrotic diseases. The company employs its Mirador360™ precision development engine, an integrated platform designed to deeply decode patient biology and accelerate the discovery and development of next-generation therapeutics in immunology and inflammation. This approach aims to identify and validate drug targets with greater accuracy.
Mark C. McKenna founded Mirador Therapeutics, alongside several other former executives from Prometheus Biosciences, which was acquired in 2023. They publicly launched Mirador in March 2024, driven by the insight that a more comprehensive, end-to-end precision medicine strategy was essential to overcome the persistent challenges in developing effective, tailored treatments for immune-mediated conditions.
The company focuses on patients suffering from a broad spectrum of immune-mediated inflammatory and fibrotic diseases, for whom existing therapies may not provide optimal outcomes. Mirador Therapeutics’ long-term vision is to establish a new paradigm in precision immunology, delivering potentially first- or best-in-class therapeutics that significantly advance patient health and treatment efficacy in these complex conditions.
Mirador Therapeutics has raised $650.0M across 2 funding rounds.
Mirador Therapeutics has raised $650.0M in total across 2 funding rounds.
Mirador Therapeutics is a biotechnology company developing precision medicines for patients with chronic immune-mediated inflammatory and fibrotic diseases.[1][2][3] It leverages the Mirador360™ precision development engine, which integrates advances in human genetics and data science to accelerate therapeutic programs in immunology and inflammation.[1][2][3] Launched in 2024 and based in San Diego, CA, the company has raised over $400 million from investors including ARCH Venture Partners, OrbiMed, and Fairmount Funds, serving patients underserved by current treatments through faster, data-driven drug development.[1][2][5] With 94 employees and a strong culture emphasizing trust, ambition, and excellence, Mirador reports 95% employee satisfaction, far above industry averages.[1][6]
Mirador Therapeutics was launched on March 21, 2024, founded by Mark C. McKenna, who serves as chairman and CEO.[2][3] McKenna previously led Prometheus Biosciences—acquired by Merck for $10.8 billion in 2023—where he oversaw over $1 billion in financing, the top biotech IPO of 2021, and the first precision therapeutics in immune-mediated diseases.[2][4] The company is led by several former Prometheus executives, bringing proven expertise from that success.[2][3] This team emerged from Prometheus' vantage point to tackle immunology and inflammation (I&I) with a fresh precision medicine approach, rapidly advancing multiple programs post-launch.[2][3]
Mirador stands out in biotech through its specialized focus and execution:
Recent hires like CFO Gregg Gilbert add 25+ years of biopharma finance expertise to fuel growth.[5]
Mirador rides the precision medicine wave in immunology, capitalizing on exponential advances in human genetics and machine learning to target fibrotic and inflammatory diseases where one-size-fits-all therapies fail.[1][2][3] Timing is ideal post-Prometheus' 2023 acquisition, validating genetics-driven I&I approaches amid rising demand for personalized treatments in a $100B+ market.[2][4] Favorable forces include surging investor interest in data-science biotech (evidenced by its $400M raise) and regulatory tailwinds for targeted therapies.[2][5] By scaling Prometheus' playbook, Mirador influences the ecosystem, accelerating "moonshot" innovations and attracting talent to San Diego's biotech hub.[1][3][6]
Mirador is poised to advance multiple therapeutic programs into clinical stages, leveraging its engine for first-in-class I&I medicines amid AI-biotech convergence.[1][2] Key trends like multimodal data integration and fibrotic disease breakthroughs will propel it, potentially mirroring Prometheus' path to acquisition or IPO.[2][4] Its influence may grow by redefining precision development speed, drawing more capital and partnerships—watch for Phase 1/2 data catalysts. This next-gen player builds directly on proven successes, positioning it to transform patient lives in immune-mediated diseases.[3]
Mirador Therapeutics has raised $650.0M across 2 funding rounds. Most recently, it raised $250.0M Series B in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 12, 2026 | $250M Series B | — | Adage Capital Management, ARCH Venture Partners, Boxer Capital, Fairmount, Farallon Capital Management, Fidelity Management & Research Company, Invus, Logos Capital, OrbiMed, Point72, TCGX, T. Rowe Price Associates, Venrock, Woodline Partners | Announced |
| Mar 1, 2024 | $400M Series A | ARCH Venture Partners | Cambridge Innovation Capital, HealthCap, Mubadala, Alexandria Venture Investments, Boxer Capital, Fairmount, Farallon Capital Management, Fidelity Management & Research Company, Invus, Logos Capital, OrbiMed, Point72, RTW Investments, Sanofi Ventures, TCGX, Venrock, Woodline Partners | Announced |
Mirador Therapeutics has raised $650.0M in total across 2 funding rounds.
Mirador Therapeutics's investors include Adage Capital Management, ARCH Venture Partners, Boxer Capital, Fairmount, Farallon Capital Management, Fidelity Management & Research Company, Invus, Logos Capital, OrbiMed, Point72, TCGX, T. Rowe Price Associates.